

Handbook of Clinical Pharmacology

Second Edition

Felix Bochner, M.D., F.R.A.C.P.

George Carruthers, M.D., M.R.C.P. (U.K.), F.R.C.P. (C), F.A.C.P.

Jens Kampmann, M.D.

Janice Steiner, M.B., D. Phil., F.R.A.C.P.

Handbook of Clinical Pharmacology

SECOND EDITION



Little, Brown and Company, Boston/Toronto

Copyright © 1983 by Little, Brown and Company (Inc.)

Second Edition

Previous edition copyright © 1978 by Little, Brown and Company (Inc.)

All rights reserved. No part of this book may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher, except by a reviewer who may quote brief passages in a review.

Library of Congress Catalog Card No. 82-84100

ISBN 0-316-10064-1

Printed in the United States of America

DONN

Notice

The indications and dosages of all drugs in this **Handbook** have been recommended in the medical literature and conform to standards generally acceptable in medical practice. The medications described do not necessarily have specific approval by the Food and Drug Administration for use in the diseases and dosages for which they are recommended. The package insert for each drug should be consulted for use and dosage as approved by the FDA. Because standards for usage change, it is advisable to keep abreast of revised recommendations, particularly those concerning new drugs.

Preface

Proliferation of drug information represents one aspect of the rapid growth of medical knowledge. Numerous studies of therapeutic indications, pharmacokinetics, and pharmacodynamics appear in the scientific literature and ultimately in textbooks, advertising copy, and circulars from drug information services and regulating agencies. However, this wealth of information often loses value through its inaccessibility in circumstances of greatest need, such as the assessment and treatment of ill patients at the bedside or in the office.

Acutely aware of this difficulty and frustrated by the lack of a convenient source of "hard" data, we began to collect, evaluate, and tabulate the available information on commonly used drugs. This led to the publication of the first edition of the *Handbook of Clinical Pharmacology*. The concept of the book was that it would be a readily available, informative source that would help solve many frequently posed problems, such as the adjustment of drug dosage in patients with renal and hepatic disease and the assessment of the importance of potential adverse effects and possible interactions of the drugs with other medications. We also believed that for those interested in gaining an in-depth knowledge of a particular drug, a short bibliography for each drug described would be helpful.

Since the *Handbook of Clinical Pharmacology* was first published in 1978, its format has been widely accepted and has been repeated in the second edition. The book has been extensively rewritten and updated with a number of new drugs added. In this edition drugs not yet available in the United States are marked with an asterisk both in the contents and in the text. These drugs are used in Europe at the time of writing, and many are likely to be licensed in the United States in due course.

We trust that the description of each drug will answer most of the questions that are asked and that the references will permit the interested reader to evaluate related literature more easily. We would also remind our readers that technical terms used in Chapter 12 are explained in detail in Chapter 11, Definition of Terms. Likewise, many of the brief statements made in the individual drug profiles in Chapter 12 are expanded in the appropriate introductory chapters. For those with no grounding in basic and clinical pharmacology, a reading of these early chapters is advisable. For those with a greater knowledge of the subject, such a reading may prove a useful review.

The fundamental goal of the book is the development of a critical and rational approach to the prescribing of drugs. It is frequently true that modern therapeutic efforts fall short of diagnostic accuracy, an unfortunate failure that may negate diagnostic excellence. We hope that this handbook will promote improved use of drugs

through a better appreciation of their activity and that the format of this text will lead to frequent, convenient consultation.

F. B.
G. C.
J. K.
J. S.

Acknowledgments

We thank the sponsoring agencies that made it possible for us to undertake fellowships in clinical pharmacology at the University of Kansas School of Medicine. Felix Bochner was a Clinical Sciences Fellow of the National Health and Medical Research Council of Australia. George Carruthers was a Fogarty International Fellow of the United States National Institutes of Health from the Queen's University and Belfast City Hospital, Northern Ireland. Jens Kampmann was the recipient of a Merck, Sharp & Dohme International Fellowship in Clinical Pharmacology from The Merck Company Foundation, Rahway, New Jersey. Janice Steiner received a traveling fellowship of the Postgraduate Medical Committee of the University of Sydney, Camperdown, New South Wales, Australia.

We are grateful to all our colleagues for their encouragement. In particular we thank Isami Shudo, M.D., for help in the early stages of preparation and Danny Shen, Ph.D., John Straughan, M.D., and Jim Hosler, M.D., for their valuable comments. Harry Shirkey, M.D., Visiting Professor of Pediatrics from Tulane University, New Orleans, Louisiana, provided helpful remarks on dosage adjustments for children.

The assistance of Maureen Jones, Lilian Kingston, Elizabeth Shaip, and Eileen Boylin, who typed the manuscript and tolerated numerous revisions, is acknowledged with deep gratitude.

Our special thanks go to Daniel L. Azarnoff, M.D., Distinguished Professor of Medicine and of Pharmacology at the University of Kansas, for all his help and guidance. In addition, Dr. Azarnoff has written a chapter on rational drug therapy that provides a stimulating introduction to the text.

Finally, we thank Lin Paterson, Cynthia Baron, and the staff of Little, Brown and Company for their expert advice and assistance at all stages of manuscript preparation.

Contents

Preface	<i>xi</i>
Acknowledgments	<i>xiii</i>

1. Do We Achieve Rational Drug Therapy?	1
DANIEL L. AZARNOFF	
2. Drug Information: A Means to Improve Prescribing	9
3. Measurement of Drugs in Plasma	19
4. Drugs and Renal Disease	25
5. Drugs and Hepatic Disease	35
6. Medication During Pregnancy	43
7. Medication During Lactation	49
8. Medication in Children	53
9. Medication in the Elderly	59
10. Acute Poisoning and Drug Overdose	65
11. Definition of Terms	75
Absorption	76
Accumulation	76
Adverse Reaction	76
Agonist	76
Antagonist	77
Area Under the Curve (AUC)	77
Binding to Plasma Proteins	77
Binding to Tissues	78
Bioavailability	78
Biopharmaceutics	78
C_{max}	79
Clearance	79
Compartment	80
Compliance	80
Disintegration	80
Dissolution	81
Distribution	81
Dose-Response Curve	81
Efficacy	82
Elimination	82
Enterohepatic Recirculation (Biliary Recycling)	82
Excretion	83
First-Order Kinetics	83
First Pass	84
Half-life: Alpha and Beta Phases	84
Hypersensitivity (Allergy)	86
Induction and Inhibition of Enzyme Activity	86
Metabolism	87
Michaelis-Menten Kinetics	88
Pharmacodynamics	89
Pharmacokinetics	89
pKa	89
Potency	90
Solubility	90
Summation (Addition)	90
Synergism (Superaddition, Potentiation)	90
t_{max}	90
Therapeutic Index	91
Therapeutic Range	91
Unbound ("Free") Drug	91
Volume of Distribution (Apparent): V_d	92
Zero-Order (Dose-Dependent or Capacity-Limited) Kinetics	92

12. Drug Profiles 95

In the following list the terms given in capital letters are subtitles within this chapter.

- * Acebutolol 122
- ACETAMINOPHEN 96
- Acetic acid derivatives 246
- ACETYSALICYLIC ACID 98
- ALBUTEROL 101
- ALLOPURINOL 103
- * Alprenolol 122
- AMANTADINE 104
- Amikacin 106
- AMINOGLYCOSIDES 106
- Amitriptyline 325
- Amoxicillin 265
- AMPHOTERICIN B 108
- Ampicillin 265
- * Ancillin 265
- Aspirin 98
- Atenolol 122
- ATROPINE 110
- Auranofin 191
- Aurothioglucose 191
- * Aurothiomalate 191
- AZATHIOPRINE 112
- * Azidocillin 265
- * Azlocillin 265
- Bacampicillin 265
- BECLOMETHASONE 114
- Bendrofluazide (Bendroflumethiazide) 320
- Benzylpenicillin 265
- BENZODIAZEPINES 116
- BETA-ADRENOCEPTOR BLOCKING AGENTS 120
- * Bethanidine 195
- BROMOCRIPTINE 126
- * Bumetanide 300
- CALCIUM SLOW-CHANNEL ANTAGONISTS 127
- CARBAMAZEPINE 129
- Carbenicillin 265
- * CARBENOXOLONE 131
- * Carbimazole 228
- * Carindacillin 265
- Cefazolin 134
- Cephalexin 134
- * Cephaloridine 134
- CEPHALOSPORINS 133
- Cephalothin 134
- Cephapirin 134
- Cephradine 134
- CHLORAL HYDRATE 136
- CHLORAMPHENICOL 137
- Chlordiazepoxide 119
- CHLOROQUINE 139
- Chlorothiazide 320
- CHLORPROMAZINE 142
- Chlorpropamide 310
- Chlortetracycline 315
- Chlorthalidone 319
- CIMETIDINE 144
- CLINDAMYCIN AND LINCOMYCIN 148
- CLONAZEPAM 149
- CLONIDINE 150
- Cloxacillin 265
- CODEINE 152
- COLCHICINE 153
- COLISTIN 155
- CONTRACEPTIVES, ORAL 157
- CORTISOL 161
- Co-trimoxazole 333
- CROMOLYN SODIUM 163
- Cyclacillin 265
- Cyclopenthiiazide 320
- CYCLOPHOSPHAMIDE 165
- * Debrisoquine 195
- Demeclocycline 315
- Desipramine 328
- Diazepam 116
- DIAZOXIDE 167
- * Diclofenac 246
- Dicloxacillin 265
- DIETHYLCARBAMAZINE 168
- DIETHYLSTILBESTROL (DES) 170
- DIGITOXIN 173
- DIGOXIN 175
- * Diltiazem 127
- DIPHENHYDRAMINE 178
- Dipropylacetate sodium 335
- Sodium cromoglycate 163
- DISOPYRAMIDE 180
- DOPAMINE AND DOBUTAMINE 181
- Doxycycline 315
- * Epicillin 265
- ERGOTAMINE 184
- ERYTHROMYCIN 186
- ETHAMBUTOL 187
- Ethinyl estradiol 157
- ETHOSUXIMIDE 188
- Estrogens 157

* Not presently available in the United States.

- Fenoprofen 249
 * Flucloxacillin 265
 Flunitrazepam (Flurazepam) 119
 FLUPHENAZINE 190
 Frusemide 300
 Furosemide 300
 Gentamicin 106
 * Glibenclamide 310
 Glyceryl trinitrate (GTN) 256
 GOLD 191
 GRISEOFULVIN 193
 Guanethidine 195
 GUANIDINIUM ANTIHYPERTENSIVE AGENTS 195
 HALOPERIDOL 197
 HEPARIN 199
 * Hetacillin 265
 HYDRALAZINE 202
 Hydrochlorothiazide 320
 Hydrocortisone 161
 Hydroflumethiazide 320
 Hyoscyamine 110
 Ibuprofen 249
 Imipramine 328
 Indomethacin 246
 INSULIN 204
 IRON 207
 Isocarboxazid 239
 ISONIAZID 209
 Isoprenaline 211
 ISOPROTERENOL 211
 Isosorbide dinitrate (ISDN) 256
 Isoxazolyl penicillins 265
 Kanamycin 106
 * Ketoprofen 249
 * LABETALOL 213
 LEVODOPA 214
 LIDOCAINE 217
 Lignocaine 217
 Lincomycin 146
 LITHIUM CARBONATE 219
 Lorazepam 119
 Maprotiline 332
 * Mecillinam 265
 MEPERIDINE 221
 Mestranol 157
 METAPROTERENOL 223
 * METFORMIN 225
 * Methacycline 315
 * METHADONE 226
 Methicillin 265
 METHIMAZOLE 228
 Methyclothiazide 319
 α -METHYLDOPA 230
 METOCLOPRAMIDE 232
 * Metoprolol 122
 METRONIDAZOLE 233
 * MEXILETINE AND *TOCAINIDE 235
 Meziocillin 265
 * Mianserin 332
 Minocycline 315
 MINOXIDIL 237
 MONOAMINE OXIDASE INHIBITORS (MAOI) 239
 MORPHINE 241
 Nafcillin 265
 NALOXONE 243
 Naproxen 249
 Neomycin 106
 * Netilmicin 106
 Newer Antidepressants 332
 * Nifedipine 127
 * Nitrazepam 120
 Nitroglycerin (NTG) 256
 NITROPRUSSIDE SODIUM 244
 * Nomifensine 332
 NONSTEROIDAL ANTI-INFLAMMATORY ANALGESICS 246
 Norethindrone 157
 * Norethisterone 157
 Norgestrel 157
 Nortriptyline 325
 NYSTATIN 254
 Orciprenaline 223
 ORGANIC NITRITES 255
 ORPHENADRINE 258
 Oxacillin 265
 Oxazepam 120
 * Oxprenolol 122
 Oxyphenbutazone 252
 Oxytetracycline 315
 OXYTOCIN 259
 PARA-AMINOSALICYLIC ACID (PAS) 261
 Paracetamol 96
 Pargyline 239
 D-PENICILLAMINE 263
 PENICILLINS 265
 PENTAZOCINE 271
 PENTOBARBITAL 272
 * Perhexiline 127
 Pethidine 221
 Phenelzine 239
 PHENOBARBITAL 274
 Phenoxyethyl penicillin 265
 Phenoxyethyl penicillin 265
 Phenoxypropyl penicillin 265
 Phenylbutazone 252
 PHENYTOIN 276

x Contents

Pindolol	122	SULFASALAZINE	303
Piperacillin	265	SULFINPYRAZONE	305
Pivampicillin	265	Sulfisoxazole	308
Polymyxin E	155	SULFONAMIDES	307
Polythiazide	319	SULFONYLUREA HYPOGLY-	
PRazosin	279	CEMIC AGENTS	310
PREDNISONE AND		Sulindac	246
PREDNISOLONE	280	*Talampicillin	265
PRIMIDONE	283	Temazepam	120
PROBENECID	285	TERBUTALINE	312
PROCAINAMIDE	287	Tetracycline	315
Progestogens	157	TETRACYCLINES	314
PROMETHAZINE	289	THEOPHYLLINE	317
PROPANTHELINE	290	THIAZIDE DIURETICS	319
Propionic acid derivatives	249	THIORIDAZINE	321
Propranolol	120	THYROXINE (T ₄) AND TRIIDO-	
Propylthiouracil	292	THYRONINE (T ₃)	322
Pyrazolone derivatives	252	Ticarcillin	265
Quinethazone	319	Timolol	122
QUINIDINE	294	Tobramycin	106
Rifampicin	296	*Tocainide	235
RIFAMPIN	296	Tolbutamide	310
Salbutamol	101	Tranylcypromine	239
Sodium nitroferricyanide	244	TRICYCLIC ANTIDEPRES-	
Sotalol	122	SANTS	325
SPIRONOLACTONE	298	TRIMETHOPRIM AND	
Streptomycin	106	SULFAMETHOXAZOLE	333
Sulfadiazine	308	VALPROATE SODIUM	335
Sulfamerazine	308	Verapamil	127
Sulfamethazine	308	WARFARIN	337
Sulfamethizole	308	*Zimelidine	332
Sulfamethoxazole	308		
SULFAMOYL "LOOP"			
DIURETICS	300		

1

Do We Achieve Rational Drug Therapy?

DANIEL L. AZARNOFF

It has been estimated that the cost of drugs was 9.3% of the \$104.2 billion spent on health care in the United States in 1974 [8]. However, the percentage is greater, since unwarranted adverse reactions to drugs contribute to the cost included in the remaining 90%. Economic losses estimated in the billions of dollars due to illness and even death brought about by today's potent drugs add further to the expense.

Stedman's Medical Dictionary [21] defines *rational therapy* as a plan of treatment of disease based on the correct interpretation of the symptoms and a knowledge of the physiologic action of the remedy. In other words, the physician must make the correct diagnosis and understand the pathophysiology of the disorder before deciding whether to treat a patient with a drug. If the answer is affirmative (and it definitely should not always be), the physician should know enough about drugs to select the right one and to administer it by the right route in the right amount at the right intervals for the right length of time. In addition, the physician must be aware of the potential for interactions with environmental, genetic, and disease-related factors. In general, physicians make the correct diagnosis with a reasonable degree of accuracy, but I am less sure that we are familiar with the pathophysiology of the disorder or the pharmacology of the drugs.

Irrational Drug Prescribing

Evidence of irrational prescribing by physicians is not difficult to find. Based on pharmaceutical production data, the consumption of prescription drugs in the United States has been estimated to have doubled over the past 10 years [20]. The average practitioner now writes about 8000 prescriptions per year. In 1975, greater than five prescriptions per capita were written in Australia, whereas from 1961 to 1971 approximately three per capita were written [24]. One must wonder if this 60% increase is the result of a more sickly population in 1975 or if the population is 60% or even 10% healthier as a result of increased drug usage. I doubt that either is true. In patients matched for age, sex, and illness, American physicians used almost 4 times as many drugs for the specific and nonspecific treatment of a variety of illnesses as did their Scottish counterparts [13]. As might be expected, the incidence of adverse effects was significantly higher in the American patients. Although it was not possible to obtain outcome results, there is no evidence that the Scottish patients were getting poorer care or were in poorer health. A review of prescribing behavior revealed that two-thirds of all outpatient physician encounters resulted in the writing of at least one prescription [14]. We must ask ourselves whether these prescriptions were warranted or were used only to get rid of the patient. The ten most common indications for a prescription drug were insomnia, pain, constipation, anxiety, con-

gestive heart failure, blood clotting, preoperative medication, bronchospasm, infection, and nausea. Described even in generous terms, we appear to be a nation of constipated, infected, wheezing, nauseated, anxious, thrombophlebitic insomniacs with failing hearts.

In an evaluation of physicians' prescribing habits, it was found that for more than 40% of prescriptions issued, the prescriber expected only a "hopeful" or "possible" value in patients with trivial conditions [15]. Greater than 90% of physicians in one community wrote one or more prescriptions for the common cold; 60% were for antibiotics or sulfonamides despite their known ineffectiveness for this condition. Unwarranted and irrational use by physicians of dangerous drugs, such as chloramphenicol, has also been documented [18]. Even though safety may not be a factor, irrational prescribing has been documented in a study in which it was estimated that in Great Britain vitamin B₁₂ usage was at least 4 times greater than the actual need [3]. Such irrational prescribing, if nothing else, adds to the cost of medical care.

Even after making the proper diagnosis and properly selecting and prescribing a drug, inadequate attention to the patient may still preclude satisfactory drug utilization. A significant number of patients never have their prescriptions filled, and even if they do, many do not take the medication as directed by the physician [1]. At least in part, inadequate communication between the physician and patient is responsible for this lack of compliance and breakdown in rational therapy.

Can physicians be utilizing drugs rationally when they continue to prescribe drugs in a manner that contradicts the current evidence? Why do the sales of sulfonylureas continue to rise when the University Group Diabetes Program (UGDP) study indicates they are of no benefit in the maturity onset diabetic and may hasten the onset of cardiovascular mortality [22]? Why are hormones still prescribed for the prevention of miscarriages or as a test for pregnancy despite the lack of evidence that they are effective for these indications, especially when they may produce birth defects [5, 9]? Why do we continue to prescribe clofibrate for the hyperlipidemic male patient with a previous myocardial infarction when this drug was demonstrated to be ineffective in preventing further cardiovascular morbidity and mortality in the Coronary Drug Project [4]? In fact, a significant increase in the incidence of thrombophlebitis, pulmonary embolus, and gallstones in patients receiving clofibrate was well documented in this study.

I believe we must conclude from these observations that drug therapy is not optimum. Rational drug therapy can no longer be based on a memorized schedule of dosage and contraindications. Drugs no longer are the herbals of yesteryear with questionable pharmacologic activity; rather, they are potent chemicals with a potential for extensive harm as well as good. The practicing physician is certainly not ignorant, negligent, nor unconcerned; he is busy and harried, working many hours per week. Importantly, however, he spends, on an average, less than 20 minutes a day reading the drug-related medical literature, which unfortunately is all too frequently inaccurate, irrelevant, unavailable, or misleading.

In considering the reasons for the lack of optimal drug therapy, we can classify drug-prescribing abuses [19] and perhaps identify the causes.

Overprescribing

Overprescribing exists when the drug is not needed or is given in a dose that is too large, for a period that is too long, or in a quantity that is too great for the patient's immediate needs. One cause of overprescribing is the use of drugs, such as sedatives, as a means of alleviating the patient's complaints when actually more complex solutions are required. The physician frequently uses the prescription as a means of terminating the visit. In a comparison of physicians and nurse practitioners it was found that after 1 year there was an increase in the use of vitamins and tonics (self-administered to some extent) in the physician-treated group of patients, whereas the use of tranquilizers and sedatives significantly decreased in the group followed by the nurses [2]. Could the difference be that the nurse practitioners took the time to talk to the patients?

Another cause of overprescribing is the desire to guarantee that everything possible that can be done has been done. This approach has been called by Kunin [11] the use of "drugs of fear," i.e., agents that help the physician resolve his own fear of failing to give the patient what he believes is the very best drug. Patients may also be responsible for the physician's overprescribing when they imply they have not received adequate attention unless they receive a prescription, or when they apply pressure to obtain a prescription that the physician would not ordinarily give. The prescribing of an antibiotic for a viral upper respiratory infection is a good example of this type of pressure. The physician assumes that if he does not prescribe the antibiotic, the patient will go to another doctor who will prescribe it, so he may as well do it.

Underprescribing

Underprescribing is the failure to prescribe a required medication, such as a drug to lower blood pressure in a hypertensive patient. Inadequate dosage or administration for too brief a period also falls in this category. The reasons for this type of abuse include overemphasis on the risk of a useful drug, skepticism about the efficacy of a drug for a particular indication, and a bad experience with a few patients in one's own practice.

Incorrect Prescribing

Incorrect prescribing occurs when the drug is given for the incorrect diagnosis, when the wrong drug is selected for the indication, or when the prescription is prepared improperly. Physicians' illegible handwriting is legendary.

Incorrect prescribing also occurs when a physician is not aware of or forgets that genetic and environmental factors or the disease process may alter the patient's response to a drug. For example, cigarette smoking may markedly accelerate the rate of elimination of a variety of drugs [17, 23]; low plasma albumin concentrations, as found in patients with the nephrotic syndrome, are associated with an increased fraction of unbound clofibrate and phenytoin, but the steady-state concentration of the unbound drug is not altered because of compensatory changes [7]; and downward dosage adjustments are necessary in patients with portacaval shunts who receive drugs with a significant first-pass effect [6].

An adverse response, such as a skin rash, is obvious to the phy-

sician and the patient, but the prevention of a satisfactory response, which is common, is much less readily discernible. Both may be the result of incorrect prescribing. For example, the "usual" dose of theophylline may not control bronchospasm in the patient who smokes, due to induction of theophylline metabolism [10], whereas inhibition of phenytoin metabolism by isoniazid may result in ataxia in patients previously showing no signs of toxicity from the same dose. The latter is most likely to occur in patients who are slow acetylators of isoniazid [12]. In this instance, the drug interaction becomes clinically significant only in individuals with certain genetic determinants.

Multiple Prescribing

Abuses caused by multiple prescribing may occur when the patient visits and receives prescriptions from more than one physician, when the patient uses nonprescription drugs along with prescription drugs, or when the physician does not withdraw one drug before starting another or prescribes a brand-name product that contains several different drugs. In such instances, the physician often forgets or is not aware that he is prescribing more than one active drug. The last, as well as other examples, provides a cogent reason for prescribing only by generic name. If it is preferred or is necessary to prescribe a specific manufacturer's product, the generic name can be written first on the prescription, followed by that of the manufacturer.

Achieving Rational Drug Therapy

Today, healthy individuals as well as those who are chronically ill may receive drugs for long periods of time. Therefore, it behooves us to eliminate unwarranted drug utilization. What is required to accomplish this goal? I believe we need several approaches:

1. Improve and extend education about the rational use of drugs, starting in medical school and continuing throughout the practitioner's career. An educational program on rational uses of digitalis was undertaken for the house staff at a Montreal hospital. Simply emphasizing the importance of body weight and renal function when prescribing loading and maintenance doses of digoxin reduced the incidence of toxicity in this hospital from 21.4% to 12.3% over a 2-year period [16].
2. Reduce both the blatant and insidious pressures from patients and commercial sources that coerce the practitioner to increase drug utilization.
3. Provide sources of unbiased information about drugs.
4. Inculcate in the physician the realization that the selection and rational use of drugs is certainly as, and possibly even more, intellectually stimulating and rewarding than making the correct diagnosis.

Once the correct diagnosis is established, we must decide whether or not drug therapy is warranted. Frequently it is not. We must remember that the designation of a drug as safe and effective by a regulatory agency means only that the drug is statistically better than a placebo. *Statistically better* may mean better by only a few percentage points and be of little, if any, clinical conse-

quence. Would you use a drug for a minor symptom if you knew the chance of producing a desirable effect was only 1 in 20? Some of us probably do.

Next we should set realistic goals by asking ourselves, "What am I trying to accomplish by administering this drug?" The goals should be both short- and long-term. For example, a short-term goal in treating diabetes mellitus would be control of the patient's blood sugar, and a long-term goal would be prevention of retinopathy and nephropathy. End points should be defined to monitor both efficacy and toxicity. To do this, the relevant physiologic, biochemical, behavioral, and physical characteristics should be measured at appropriate intervals. The patient's condition is not static. Therefore, we must continually review our treatment regimen and make any changes that are necessary by alterations in the patient's disease or response. All too often we prescribe a drug, such as digitalis for congestive heart failure, and years later the patient is still taking the drug at the same dosage originally prescribed. In the interim we have given little if any consideration to whether or not the use or initial dosage of this drug is still appropriate.

I have briefly set forth my views on the current status of drug therapy and made several broad suggestions for improvement. A major need is for nonbiased drug information. You may imagine my pleasure when the authors of this book informed me that they were gathering and critically reviewing the pharmacokinetic data available for many of the most commonly used drugs. As well-trained internists as well as clinical pharmacologists, Drs. Bochner, Carruthers, Kampmann, and Steiner are well qualified for this undertaking. For months I watched them put the information they gathered to use at the bedside of many patients. Soon it became obvious that their colleagues could also use the information profitably and, so, this book.

We should all strive to maximize the rational use of drugs, not rationalize the maximal use of drugs. This book will be a great help.

References

1. Blackwell, B. The drug defaulter. *Clin. Pharmacol. Ther.* 13:841-848, 1972.
2. Chaiton, A., Spitzer, W. O., et al. Patterns of drug use: A community focus. *Can. Med. Assoc. J.* 114:33-37, 1976.
3. Cochrane, A. L., and Moore, F. Expected and observed values for the prescription of vitamin B₁₂ in England and Wales. *Br. J. Prev. Soc. Med.* 25:147-151, 1971.
4. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. *J.A.M.A.* 231:360-381, 1975.
5. Dieckmann, W. J., Davis, M. E., et al. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? *Am. J. Obstet. Gynecol.* 66:1062-1075, 1953.
6. Gugler, R., Lain, P., et al. Effect of portacaval shunt on the disposition of drugs with and without first pass effect. *J. Pharmacol. Exp. Ther.* 195:416-423, 1975.
7. Gugler, R., Shoeman, D. W., et al. Pharmacokinetics of drugs in patients with the nephrotic syndrome. *J. Clin. Invest.* 55:1182-1189, 1975.
8. *Health in the United States (1975)*. (A chartbook: Department of Health, Education and Welfare publication [HRA] 76-1233.) Washington, D.C.: U.S. Government Printing Office, 1976.

9. Herbst, A. L., Poskanzer, D. C., et al. Prenatal exposure to stilbestrol: A prospective comparison of exposed female offspring with unexposed controls. *N. Engl. J. Med.* 292:334-339, 1975.
10. Hunt, S. N., Jusko, W. J., et al. Effect of smoking on theophylline disposition. *Clin. Pharmacol. Ther.* 19:546-551, 1976.
11. Kunin, C. M. Use of antibiotics: A brief exposition of the problem and some tentative solutions. *Ann. Intern. Med.* 79:555-560, 1973.
12. Kutt, H., Brennan, R., et al. Diphenylhydantoin intoxication: A complication of isoniazid therapy. *Am. Rev. Resp. Dis.* 101:377-384, 1970.
13. Lawson, D. H., and Jick, H. Drug prescribing in hospitals: An international comparison. *Am. J. Public Health* 66:644-648, 1976.
14. *National Disease and Therapeutic Index.* (Reference File, Diagnosis, July 1967-June 1968.) Ambler, Pa.: Lea Assoc., 1968.
15. *National Disease and Therapeutic Index.* (Reference File, Diagnosis, The common cold, October 1967-September 1968.) Ambler, Pa.: Lea Assoc., 1968.
16. Ogilvie, R. I., and Ruedy, J. An educational program in digitalis therapy. *J.A.M.A.* 222:50-55, 1972.
17. Pantuck, E. J., Kuntzman, R., et al. Decreased concentration of phenacetin in plasma of cigarette smokers. *Science* 175:1248-1250, 1972.
18. Ray, W. A., Federspiel, C. F., et al. Prescribing of chloramphenicol in ambulatory practice. *Ann. Intern. Med.* 84:266-270, 1976.
19. Report by Working Party 1975, Council of Europe, European Public Health Community. Abuses of medicines: II. Prescription medicines. *Drug Intel. Clin. Pharm.* 10:94-110, 1976.
20. Rucker, D. T., Drug use: Data, sources and limitations. *J.A.M.A.* 230:880-890, 1974.
21. *Stedman's Medical Dictionary* (23rd ed.). Baltimore: Williams & Wilkins, 1976.
22. The University Group Diabetes Program. A study of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. *Diabetes* 19 (Suppl. 2):789-830, 1970.
23. Vaughn, D. P., and Beckett, A. H. The influence of smoking on the inter-subject variation in pentazocine elimination. *Br. J. Clin. Pharmacol.* 3:279-283, 1976.
24. Wade, D. N. The background pattern of drug usage in Australia. *Clin. Pharmacol. Ther.* 19:651-656, 1976.

